文献速递肿瘤 PET/CT核素与放射性配体治疗

治疗前18F-RGD PET/CT血管生成显像或可预测抗血管生成治疗反应

Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-05

前瞻性临床试验纳入拟接受阿帕替尼二线或三线单药治疗的可测量实体瘤患者,治疗前行18F-RGD PET/CT,分析示踪剂摄取与抗血管生成疗效的关系。25例患者42个可测量病灶中,应答肿瘤的SUVpeak和SUVmean显著高于非应答肿瘤,基线高SUVmean与更长的无进展生存期相关。18F-RGD PET/CT摄取或可预测抗血管生成治疗反应。

要点

  • 应答肿瘤SUVpeak 4.98±2.34 vs 非应答3.59±1.44(p=0.048),SUVmean 3.71±1.15 vs 2.95±0.49(P=0.036)。
  • SUVmax在应答与非应答肿瘤间无显著差异(6.58±3.33 vs 4.74±1.83,P=0.078)。
  • 基线SUVmean以3.82为阈值,高SUVmean组PFS 5.0个月 vs 3.4个月(log-rank P=0.036)。

核心结论

  • 治疗前18F-RGD PET/CT显像的示踪剂摄取或可预测抗血管生成治疗反应,肿瘤18F-RGD摄取越高,预示阿帕替尼治疗反应越好。

研究设计与样本

  • 前瞻性临床试验,纳入拟接受阿帕替尼二线或三线单药治疗的可测量实体瘤患者,治疗前行18F-RGD PET/CT检查。
  • 38例患者同意参与研究,25例患者共42个可测量病灶纳入疗效评估分析。
  • 中位随访时间3个月(范围1-10个月),中位无进展生存期3个月(95%CI 1.04-4.96)。

主要发现

  • 应答肿瘤SUVpeak为4.98±2.34,非应答肿瘤为3.59±1.44(p=0.048),应答肿瘤显著更高。
  • 应答肿瘤SUVmean为3.71±1.15,非应答肿瘤为2.95±0.49(P=0.036),应答肿瘤显著更高。
  • 应答肿瘤与非应答肿瘤SUVmax分别为6.58±3.33与4.74±1.83,差异无统计学意义(P=0.078)。
  • 探索性ROC曲线分析显示SUVmean的AUC为0.700,优于SUVpeak的AUC 0.689。
  • 以3.82为阈值,基线高SUVmean与改善的PFS相关(5.0个月 vs 3.4个月,log-rank P=0.036)。

关键数值与推荐

  • SUVpeak预测疗效的ROC曲线AUC为0.689,SUVmean的AUC为0.700。
  • 基线SUVmean阈值3.82用于区分PFS,高SUVmean组5.0个月 vs 低SUVmean组3.4个月(log-rank P=0.036)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore the relationship between metabolic uptake of the 18F-ALF-NOTA-PRGD2 (18F-RGD) tracer on positron emission tomography/computerized tomography (PET/CT) and the antiangiogenic effect of apatinib in patients with solid malignancies. MATERIALS AND PATIENTS: Patients with measurable lesions scheduled for second- or third-line single-agent therapy with apatinib were eligible for this prospective clinical trial. All patients underwent 18F-RGD PET/CT examination before the start of treatment. Standardized uptake values (SUVs) of contoured tumor lesions were computed and compared using independent sample t-tests or the Mann-Whitney U test. Receiver-operating characteristic (ROC) curve analysis was used to determine accuracy in predicting response. Survival curves were compared using the Kaplan-Meier method. RESULTS: Of 38 patients who consented to study participation, 25 patients with 42 measurable lesions met the criteria for inclusion in this response assessment analysis. The median follow-up time was 3 months (range, 1-10 months), and the median progression-free survival (PFS) was 3 months (95% confidence interval, 1.04-4.96). The SUVpeak and SUVmean were significantly higher in responding tumors than in non-responding tumors (4.98 ± 2.34 vs 3.59 ± 1.44, p = 0.048; 3.71 ± 1.15 vs 2.95 ± 0.49, P = 0.036). SUVmax did not differ between responding tumors and non-responding tumors (6.58 ± 3.33 vs 4.74 ± 1.83, P = 0.078). An exploratory ROC curve analysis indicated that SUVmean [area under the ROC curve (AUC) = 0.700] was a better parameter than SUVpeak (AUC = 0.689) for predicting response. Using a threshold value of 3.82, high SUVmean at baseline was associated with improved PFS (5.0 vs. 3.4 months, log-rank P = 0.036). CONCLUSION: 18F-RGD uptake on PET/CT imaging pretreatment may predict the response to antiangiogenic therapy, with higher 18F-RGD uptake in tumors predicting a better response to apatinib therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li L, Ma L, Shang D, et al. Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. Eur J Nucl Med Mol Imaging. 2018. PMID: 30187104. doi:10.1007/s00259-018-4143-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。